World Journal of Mens Health最新文献

{"title":"Plasma Metabolomic Signatures Linked to Healthy Lifestyle and Risk of Benign Prostatic Hyperplasia.","authors":"Shengzhuo Liu, Kai Ma, Xiaoyang Liu, Fan Zhang, Jiayu Liang, Xianding Wang","doi":"10.5534/wjmh.250306","DOIUrl":"https://doi.org/10.5534/wjmh.250306","url":null,"abstract":"<p><strong>Purpose: </strong>The aim of this study was to identify and validate a plasma metabolomic signature associated with healthy lifestyle and to examine their relationship with the risk of incident benign prostatic hyperplasia (BPH).</p><p><strong>Materials and methods: </strong>From the UK Biobank, 89,388 male participants without baseline BPH were analyzed. Healthy lifestyle scores were calculated based on smoking status, alcohol consumption, physical activity, and sleep duration. Nuclear magnetic resonance-based metabolomics profiling was conducted on ethylenediaminetetraacetic plasma samples, measuring 251 metabolic biomarkers. An elastic net regression developed a metabolic signature representing a healthy lifestyle. Cox proportional hazard models assessed the associations between lifestyle, metabolic signature, and BPH risk, adjusting for confounders. Mediation analysis explored the metabolic signature's role in the lifestyle-BPH risk relationship.</p><p><strong>Results: </strong>Results showed that higher healthy lifestyle scores correlated with reduced BPH risk, with a hazard ratio (HR) of 0.94 per one-point increase (95% confidence interval [CI]: 0.92 to 0.96). A metabolic signature of 83 metabolites was identified, significantly linked to healthier lifestyles and independently associated with lower BPH risk (HR=0.78, 95% CI: 0.72 to 0.83). Mediation analysis indicated that 19.7% (95% CI: 13.7% to 29.6%) of the lifestyle-BPH risk association was mediated by this signature, mainly through lipoprotein particles, cholesteryl esters in high-density lipoprotein, and phosphatidylcholines.</p><p><strong>Conclusions: </strong>In conclusion, healthy-lifestyle related metabolites were associated with a reduced risk of BPH. The findings highlight the potential of using metabolic signatures as biomarkers for personalized health strategies to reduce BPH incidence. Future research should aim to validate these results across diverse populations and investigate the long-term dynamics of lifestyle-induced metabolic changes.</p>","PeriodicalId":54261,"journal":{"name":"World Journal of Mens Health","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148392521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treating Erectile Dysfunction in Phosphodiesterase 5 Inhibitors Failures - Established Therapies and Newer Options.","authors":"Edoardo Pescatori, Aleksei Ryzhkov, Selahittin Cayan, Germar-M Pinggera, Widi Atmoko, Taras Shatylko, Marlon Martinez, Quang Nguyen, Tan V Le, Rupin Shah, Ashok Agarwal","doi":"10.5534/wjmh.260032","DOIUrl":"https://doi.org/10.5534/wjmh.260032","url":null,"abstract":"","PeriodicalId":54261,"journal":{"name":"World Journal of Mens Health","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148392547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Correlation between Insulin Resistance Indexes and Single-Measurement Low Total Testosterone in Korean Male Health Examination Participants.","authors":"Dong Jin Park, Sin Woo Lee, Suzi Park, Jun Ho Lee","doi":"10.5534/wjmh.250435","DOIUrl":"https://doi.org/10.5534/wjmh.250435","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to determine which insulin resistance (IR) marker served as the strongest predictor of single-measurement low total testosterone (SLTT) in a Korean male population.</p><p><strong>Materials and methods: </strong>A dataset of male participants who underwent health checkups at a university hospital in Seoul, South Korea, between 2010 and 2020 was collated. The preliminary health screening included the following elements: age, medical history, body mass index (BMI), blood pressure measurements, basic blood chemistry, lipid profile analyses, and hemoglobin A1c level. This study aimed to compare the correlation between SLTT and IR markers. Three IR markers (triglyceride-glucose index [TyG], TyG-BMI, triglyceride-to-high-density lipoprotein ratio [TG/HDL]) were evaluated in this study.</p><p><strong>Results: </strong>Among 3,225 patients, 734 (22.7%) were identified as having SLTT. Moreover, SLTT was correlated with TyG, TyG-BMI, and TG/HDL cholesterol ratio. Participants were divided into four groups based on the IR marker quartiles. For TyG-BMI and TG/HDL, the odds ratios for the third and fourth quartile groups were significantly different from those for the first quartile group after full adjustment. The cut-off values of TyG, TyG-BMI, and TG/HDL cholesterol for SLTT were 8.64, 217.79, and 2.45, respectively. The area under the receiver operating characteristic curve was greatest for TyG-BMI, followed by TG/HDL and TyG.</p><p><strong>Conclusions: </strong>Our findings demonstrated significant associations between TyG, TyG-BMI, TG/HDL index, and SLTT in the Korean male population. In addition, TyG-BMI demonstrated superior predictive capability for identifying SLTT compared with TyG and TG/HDL.</p>","PeriodicalId":54261,"journal":{"name":"World Journal of Mens Health","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148392535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dehydroepiandrosterone Sulfate/Cortisol Ratio as a Biomarker of Depressive Symptoms in Late-Onset Hypogonadism: An Analysis of 3,005 Males.","authors":"Haruhiko Wakita, Riho Kasai, Yukiko Ota, Takashi Kanda, Yuta Anno, Keisuke Ishikawa, Ayumu Taniguchi, Yuka Uesaka, Taiji Nozaki, Masato Shirai, Kazuhiro Kobayashi, Akira Tsujimura","doi":"10.5534/wjmh.250393","DOIUrl":"https://doi.org/10.5534/wjmh.250393","url":null,"abstract":"<p><strong>Purpose: </strong>Depressive symptoms related to late-onset hypogonadism (LOH) have attracted attention due to their impact on absenteeism and presenteeism. Although LOH symptoms are not consistently associated with serum testosterone levels, elevated cortisol and decreased dehydroepiandrosterone sulfate (DHEA-S) are frequently observed in depressed individuals, suggesting their potential as biomarkers. We investigated the relationship between depressive symptoms and the DHEA-S/cortisol (D/C) ratio in a large cohort of males with LOH symptoms.</p><p><strong>Materials and methods: </strong>We retrospectively analyzed data from 3,005 males with LOH symptoms who visited our hospital or affiliates between May 2016 and March 2024. Symptoms were assessed using the Aging Male Symptoms (AMS) scale, Sexual Health Inventory for Men, International Prostate Symptom Score, and Beck Depression Inventory (BDI). Endpoints included correlations between serum testosterone and D/C ratio, associations between the D/C ratio and AMS and BDI scores, and multivariable-adjusted relationships between the D/C ratio and symptom scores.</p><p><strong>Results: </strong>The mean age was 47.5±12.3 years, mean serum testosterone of 5.4±2.4 ng/mL and mean D/C ratio of 33.8±29.2. No significant correlation was observed between testosterone and D/C ratio (p=0.368). In contrast, the D/C ratio showed significant negative correlations with AMS (r=-0.058, p=0.001) and BDI (r=-0.085, p<0.001) scores. Trend analysis demonstrated a decline in the D/C ratio with increasing AMS and BDI severity (p for trend<0.001). Testosterone showed no association with AMS or BDI scores. After adjusting for age, aminotransferase, alanine aminotransferase, γ-glutamyl transpeptidase, total cholesterol, triglyceride, hemoglobin A1c, only the BDI score remained associated with the D/C ratio (β=-0.054, p=0.002).</p><p><strong>Conclusions: </strong>The D/C ratio demonstrates a significant association with depressive symptoms and may serve as a potential biomarker. Its assessment may improve psychological evaluations and management in this population.</p>","PeriodicalId":54261,"journal":{"name":"World Journal of Mens Health","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148392611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging Diagnosis and Treatment of Male Infertility: Hope versus Reality.","authors":"Widi Atmoko, Selahittin Çayan, Edoardo Pescatori, Quang Nguyen, Germar-Michael Pinggera, Taras Shatylko, Tan V Le, Aleksei Ryzhkov, Marlon P Martinez, Nguyen Ho Vinh Phuoc, Ashok Agarwal","doi":"10.5534/wjmh.260030","DOIUrl":"https://doi.org/10.5534/wjmh.260030","url":null,"abstract":"","PeriodicalId":54261,"journal":{"name":"World Journal of Mens Health","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148392563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Personalized Management of Non-Obstructive Azoospermia: Current Evidence, Clinical Strategies, and Future Directions.","authors":"Erman Ceyhan, Amarnath Rambhatla, Rupin Shah, Germar-Michael Pinggera, Taha Hamoda, Mohammed Abdulgabbar Noman, Mohamed Arafa, Ashok Agarwal","doi":"10.5534/wjmh.260007","DOIUrl":"https://doi.org/10.5534/wjmh.260007","url":null,"abstract":"","PeriodicalId":54261,"journal":{"name":"World Journal of Mens Health","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148392601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes and Predictors in Hypogonadal Oligospermic Men Treated with Clomiphene Citrate.","authors":"Edoardo Pozzi, Simona De Luca, Gabriele Birolini, Massimiliano Raffo, Fausto Negri, Christian Corsini, Alessandro Bertini, Luca Boeri, Marco Oddo, Luca Pagliardini, Alessia d'Arma, Francesco Montorsi, Andrea Salonia","doi":"10.5534/wjmh.250371","DOIUrl":"https://doi.org/10.5534/wjmh.250371","url":null,"abstract":"<p><strong>Purpose: </strong>To determine response rates and predictors of circulating testosterone and sperm concentration improvement in hypogonadal men with oligospermia treated with clomiphene citrate 50 mg daily.</p><p><strong>Materials and methods: </strong>Records of 166 men with testosterone <3.5 ng/mL and sperm concentration <15 million/mL treated for ≥3 months between January 2020-2025 were retrospectively analyzed. Testosterone responders were defined as achieving T ≥3.5 ng/mL. Sperm concentration responders were defined as those with any improvement. Multivariate logistic regression identified predictors of treatment response for both outcomes.</p><p><strong>Results: </strong>Overall, 151 men (91%) normalized testosterone, with median levels rising from 2.9 (interquartile range 2.8-2.9) to 4.6 (3.9-5.5) ng/mL, a median increase of 1.7 (0.6-2.3) ng/mL (p<0.001). Sperm concentration improved in 118 men (71%), increasing from 4.0 (1.4-8.0) to 5.6 (2.1-10.9) million/mL, a median gain of 1.6 (0.7-2.9) million/mL (p=0.01). However, 48 men (29%) experienced a paradoxical decline, with a median decrease of -3.3 (-6.6 to 0.0) million/mL. Baseline estradiol independently predicted testosterone response (odds ratio [OR] 1.06, 95% confidence interval [CI] 1.01-1.35, p=0.04), while lower baseline sperm concentration predicted greater sperm improvement (OR 0.84, 95% CI 0.70-0.99, p=0.04).</p><p><strong>Conclusions: </strong>Clomiphene citrate 50 mg daily normalized testosterone in 9 of 10 men with hypogonadism and oligospermia. Baseline estradiol predicted testosterone response, while sperm improvements were more likely in men with lower baseline counts. Although sperm concentration increased in most patients, clinical relevance was modest and nearly one-third worsened. Clomiphene citrate may be considered for testosterone optimization, particularly in men with higher estradiol, but fertility expectations should be managed.</p>","PeriodicalId":54261,"journal":{"name":"World Journal of Mens Health","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148631982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early Prostate-Specific Antigen Dynamics as Predictors of Treatment Response and Survival Outcomes in Patients with Castration-Resistant Prostate Cancer and Bone Metastases Undergoing Radium-223 Therapy.","authors":"Hui-Ying Liu, Chun-Yi Jen, Yin-Lun Chang, Yen-Ting Wu, Yu-Li Su, Yen-Hao Chen, Yen-Hsiang Chang, Hung-Jen Wang, Yen-Ta Chen, Yao-Chi Chuang, Yuan-Tso Cheng, Chih-Hsiung Kang, Chien-Hsu Chen, Yuan-Chi Shen, Yi Yang Liu, Hao-Lun Luo","doi":"10.5534/wjmh.250053","DOIUrl":"https://doi.org/10.5534/wjmh.250053","url":null,"abstract":"<p><strong>Purpose: </strong>Radium-223 (Ra-223) is a bone-targeting radiopharmaceutical used to treat symptomatic bone metastases in men with castration-resistant prostate cancer (CRPC), but there are no reliable biomarkers to guide timely therapeutic adjustments. This study explored the prognostic significance of early prostate-specific antigen (PSA) dynamics during Ra-223 therapy in patients with CRPC and bone metastases.</p><p><strong>Materials and methods: </strong>This multi-institutional, retrospective cohort study analyzed 243 patients with CRPC and bone metastases treated with Ra-223 between January 2018 and December 2023 at Chang Gung Memorial Hospital, Taiwan. PSA and alkaline phosphatase (ALP) levels were recorded before and after two cycles of Ra-223 treatment (PSA 2M, ALP 2M). Additionally, the association between PSA, ALP, and clinical outcomes, including response, visceral metastasis-free survival (VMFS), and overall survival (OS), was assessed. Kaplan-Meier analysis, multivariate Cox regression, and receiver operating characteristic curve analysis were used to evaluate the prognostic value of PSA 2M.</p><p><strong>Results: </strong>Patients whose PSA 2M increase≤40% demonstrated significantly better pain control (p=0.003), improved VMFS (p=0.005), and longer OS (p=0.012) compared to those whose PSA 2M increase>40%. Kaplan-Meier analyses confirmed shortened VMFS (p=0.005) and OS (p=0.012) in patients with a PSA 2M increase of >40%. In multivariate Cox regression analyses, baseline opioid use and completion of Ra-223 injections were independent predictors of VMFS, while baseline ALP>94, PSA 2M increase>40%, and completion of Ra-223 injections were independently associated with OS.</p><p><strong>Conclusions: </strong>Early PSA dynamics during Ra-223 therapy can predict clinical outcomes in patients with CRPC and bone metastases. Patients with a PSA 2M increase of >40% had worse pain control, shorter VMFS and OS, and may benefit from early therapeutic modifications, including combination therapies. These findings underscore the importance of early biomarker-driven interventions to optimize treatment outcomes.</p>","PeriodicalId":54261,"journal":{"name":"World Journal of Mens Health","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148139756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global Andrology Forum Position Statements on Regenerative Therapies for Erectile Dysfunction.","authors":"Taha Hamoda, Selahittin Çayan, Manaf Al Hashimi, Eric Chung, Maged Ragab, Omer Raheem, Taymour Mostafa, Akira Tsujimura, Tuncay Toprak, Germar-Michael Pinggera, Marco Falcone, Manh Truong Nguyen, Tan V Le, Abheesh Varma Hegde, Marlon Pedrozo Martinez, Kadir Böcü, Mohamed Arafa, Raghavender Kosgi, Luca Boeri, Haitham Elbardisi, Taras Shatylko, Charalampos Konstantinidis, Hiva Alipour, Rupin Shah, Ashok Agarwal","doi":"10.5534/wjmh.250421","DOIUrl":"https://doi.org/10.5534/wjmh.250421","url":null,"abstract":"<p><strong>Purpose: </strong>Phosphodiesterase type 5 inhibitors (PDE5i) are widely used to treat erectile dysfunction (ED). However, a subset of men does not respond to these agents or seek restoration of natural erections. Regenerative therapies (RT), including low-intensity shock wave therapy (LiSWT), platelet-rich plasma (PRP) therapy, and stem cell therapy (SCT), have emerged as potential alternative treatment options. This article reviews the available evidence and presents the Global Andrology Forum (GAF) graded statements and recommendations for the use of RT in ED.</p><p><strong>Materials and methods: </strong>A GAF expert panel conducted a literature review of the PubMed and Scopus databases up to February 2025 to identify studies on RT for ED. Surveys and a modified Delphi consensus method were employed to develop position statements and clinical recommendations. These were graded according to the \"GRADE\" classification system as either \"strong\" or \"weak.\" Recommendations receiving strong ratings from at least 80% of experts were classified as \"strong,\" while others were classified as \"weak.\"</p><p><strong>Results: </strong>Seventeen statements and recommendations were accepted and graded by a panel of 36 GAF experts from 18 countries. Eleven were classified as \"strong,\" and six as \"weak.\"</p><p><strong>Conclusions: </strong>Current evidence indicates modest short-term benefits of LiSWT in young and middle-aged men with mild-to-moderate vasculogenic ED. The efficacy of PRP and SCT remains uncertain. The GAF statements and recommendations highlight the lack of standardized treatment protocols and insufficient evidence of long-term effectiveness and emphasize the need for further research and clinical trials. Meanwhile, patients and healthcare providers should remain cautious when applying RT for ED. Clinicians should avoid overclaiming the benefits of RT to patients and provide a realistic prognosis based on current evidence.</p>","PeriodicalId":54261,"journal":{"name":"World Journal of Mens Health","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148631937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond Heat Stress: Varicocelectomy as a Strategy for Sleep-Mediated Endocrine Optimization in Non-Obstructive Azoospermia.","authors":"Yu-Hsiang Lin","doi":"10.5534/wjmh.260035","DOIUrl":"https://doi.org/10.5534/wjmh.260035","url":null,"abstract":"","PeriodicalId":54261,"journal":{"name":"World Journal of Mens Health","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148139753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}